HomeCompareAVVH vs PFE

AVVH vs PFE: Dividend Comparison 2026

AVVH yields 66666.67% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AVVH wins by $8.441837856534449e+24M in total portfolio value
10 years
AVVH
AVVH
● Live price
66666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.441837856534449e+24M
Annual income
$8,417,001,582,403,749,000,000,000,000,000.00
Full AVVH calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — AVVH vs PFE

📍 AVVH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAVVHPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AVVH + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AVVH pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AVVH
Annual income on $10K today (after 15% tax)
$5,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$7,154,451,345,043,187,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, AVVH beats the other by $7,154,451,345,043,187,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AVVH + PFE for your $10,000?

AVVH: 50%PFE: 50%
100% PFE50/50100% AVVH
Portfolio after 10yr
$4.2209189282672247e+24M
Annual income
$4,208,500,791,201,874,400,000,000,000,000.00/yr
Blended yield
99.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

AVVH
No analyst data
Altman Z
-27.1
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AVVH buys
0
PFE buys
0
No recent congressional trades found for AVVH or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAVVHPFE
Forward yield66666.67%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$8.441837856534449e+24M$49.6K
Annual income after 10y$8,417,001,582,403,749,000,000,000,000,000.00$26,258.71
Total dividends collected$8.44020886744369e+24M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AVVH vs PFE ($10,000, DRIP)

YearAVVH PortfolioAVVH Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$6,677,367$6,666,666.67$9,153$693.39+$6.67MAVVH
2$4,167,497,846$4,160,353,063.34$8,593$849.25+$4167.49MAVVH
3$2,431,161,901,635$2,426,702,678,939.67$8,336$1,066.78+$2431161.89MAVVH
4$1,325,636,209,022,888$1,323,034,865,788,139.00$8,437$1,384.80+$1325636209.01MAVVH
5$675,632,775,263,916,700$674,214,344,520,262,300.00$9,013$1,875.40+$675632775263.91MAVVH
6$321,867,481,182,444,260,000$321,144,554,112,911,900,000.00$10,306$2,680.72+$321867481182444.25MAVVH
7$143,326,993,661,751,470,000,000$142,982,595,456,886,240,000,000.00$12,820$4,101.38+$143326993661751472.00MAVVH
8$59,657,925,421,851,500,000,000,000$59,504,565,538,633,426,000,000,000.00$17,673$6,826.70+$59657925421851500544.00MAVVH
9$23,211,471,150,187,795,000,000,000,000$23,147,637,169,986,416,000,000,000,000.00$27,543$12,591.86+$2.3211471150187796e+22MAVVH
10$8,441,837,856,534,450,000,000,000,000,000$8,417,001,582,403,749,000,000,000,000,000.00$49,560$26,258.71+$8.441837856534449e+24MAVVH

AVVH vs PFE: Complete Analysis 2026

AVVHStock

AVVAA World Health Care Products, Inc. provides natural and therapeutic skin care products worldwide. The company is a biotechnology company which primarily focuses on manufacturing and marketing over-the-counter the Neuroskin line of products used for the treatment of skin abnormalities, and to enhance the natural clarity and texture of healthy skin through mass marketing food and drug channels. It also has distribution rights for patented European skin care products, which are scientifically developed to treat the symptoms of skin diseases, including eczema, psoriasis, and acne. The company also offers a line of natural animal care products, which is a grooming treatment for dogs, cats, horses, and other pets. AVVAA World Health Care Products, Inc. was incorporated in 1998 and is based in Richmond, Virginia. As of June 23, 2021, AVVAA World Health Care Products, Inc. operates as a subsidiary of Gold Quest Capital, Inc.

Full AVVH Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this AVVH vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AVVH vs SCHDAVVH vs JEPIAVVH vs OAVVH vs KOAVVH vs MAINAVVH vs JNJAVVH vs MRKAVVH vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.